Vanguard Group Inc lowered its position in Petmed Express Inc (NASDAQ:PETS) by 16.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,003,180 shares of the company’s stock after selling 405,786 shares during the period. Vanguard Group Inc owned 9.69% of Petmed Express worth $66,125,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in PETS. Schwab Charles Investment Management Inc. boosted its holdings in Petmed Express by 3.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 106,937 shares of the company’s stock worth $4,711,000 after acquiring an additional 3,212 shares in the last quarter. BlackRock Inc. boosted its holdings in Petmed Express by 9.8% in the second quarter. BlackRock Inc. now owns 2,917,663 shares of the company’s stock worth $128,523,000 after acquiring an additional 260,789 shares in the last quarter. Legal & General Group Plc boosted its holdings in Petmed Express by 7.3% in the second quarter. Legal & General Group Plc now owns 40,808 shares of the company’s stock worth $1,806,000 after acquiring an additional 2,783 shares in the last quarter. OppenheimerFunds Inc. bought a new position in Petmed Express in the second quarter worth approximately $205,000. Finally, Voya Investment Management LLC boosted its holdings in Petmed Express by 56.2% in the second quarter. Voya Investment Management LLC now owns 36,042 shares of the company’s stock worth $1,588,000 after acquiring an additional 12,961 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
Shares of Petmed Express stock opened at $23.44 on Friday. The firm has a market cap of $484.60 million, a P/E ratio of 11.27 and a beta of 0.74. Petmed Express Inc has a 12 month low of $21.61 and a 12 month high of $57.80.
Petmed Express (NASDAQ:PETS) last issued its quarterly earnings results on Monday, October 22nd. The company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.02. The business had revenue of $71.40 million for the quarter, compared to analyst estimates of $71.93 million. Petmed Express had a return on equity of 35.53% and a net margin of 14.88%. Petmed Express’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share.
Several research analysts have issued reports on the company. BidaskClub lowered Petmed Express from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. ValuEngine lowered Petmed Express from a “sell” rating to a “strong sell” rating in a report on Monday, October 8th. Finally, TheStreet lowered Petmed Express from a “b” rating to a “c+” rating in a report on Thursday, November 29th. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $35.00.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/20/petmed-express-inc-pets-position-reduced-by-vanguard-group-inc.html.
Petmed Express Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Read More: What is a Stop Order?
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.